Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01131325 · ClinicalTrials.gov registry record · Phase 4
Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations
A Phase 4 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 4
- Development phase
- 3
- Enrollment target
NCT01131325 is a Phase 4 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 3 participants.
The verdict
NCT01131325, a Phase 4 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 3 participants
- Enrollment target
Study Summary
This study is to determine the number of European Leukemia Network (ELN)guideline defined treatment failure events from time of study entry in CML-CP patients with low imatinib trough concentrations treated with nilotinib.
Interventions
- DRUG nilotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2010-10-21 |
| Est. Completion | 2011-05-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01131325
The ClinicalTrials.gov registry entry for NCT01131325 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which nilotinib is the first listed.
NCT01131325 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01131325 about?
NCT01131325 is a clinical study titled "Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations". This study is to determine the number of European Leukemia Network (ELN)guideline defined treatment failure events from time of study entry in CML-CP patients with low imatinib trough concentrations treated with nilotinib.
What is the current status of trial NCT01131325?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 3 participants. The study started on 2010-10-21. Estimated completion is 2011-05-12.
What interventions are being tested in trial NCT01131325?
The interventions under investigation include: nilotinib (DRUG).
Who is sponsoring clinical trial NCT01131325?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.